Related Experiment Videos
Both populations and individuals are evolutionary targets: pharmacogenomic and cultural indicators
1Department of Pharmacology, University of Toronto, Canada. w.kalow@utoronto.ca
The Pharmacogenomics Journal
|May 7, 2002
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine.
The pharmacogenomics journal·2006
Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine.
European journal of clinical pharmacology·2001
CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Journal of clinical psychopharmacology·2001
Perspectives in pharmacogenetics.
Archives of pathology & laboratory medicine·2001
Amplicon-based long-read sequencing for accurate CYP2D6 gene deletion and duplication detection using CYP2D7 as a reference gene.
The pharmacogenomics journal·2026
Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects.
The pharmacogenomics journal·2026
Effects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation.
The pharmacogenomics journal·2026
Understanding public perspectives on direct-to-consumer pharmacogenomic testing in the UK: a qualitative study.
The pharmacogenomics journal·2026
Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants.
The pharmacogenomics journal·2026